Skip to main content

Table 1 Treatment patterns among adult patients across select countries/regions

From: Review on epidemiology, disease burden, and treatment patterns of IgA nephropathy in select APAC countries

Author year

Cohort age a

Sample size

ACEI/ARBs (%)

Other therapies (%) e

Mainland China

Wen 2021 [29]

32.7 ± 11.1 (Male); 34.7 ± 10.8 (Female)

1096

38

Steroid (36.1), immunosuppressant (25.9)

Zhu 2021 [32]

35.5 ± 9.1

102

78.4

Steroid (100), tonsillectomy (27.5), intravenous methylprednisolone (15.7), plasma exchange (8.8)

Liu 2020 [28]

37.76 ± 12.1

246

69.1

CTX + steroid (55.7), steroid (52.8)

Tian 2020 [26]

33.8 ± 11.6

172

55.8

Steroid (32.6), steroid + immunosuppressant (9.9), immunosuppressant (7.6)

Zhou 2017 [15]

36 (28–43) b

375

66.7

Calcium channel blockers (29.1), corticosteroid (20), β-blocker (14.9), allopurinol (6.7), α-blocker (3.7), immunosuppressant (1.6), diuretics (0.8)

Le 2011 [42]

30.6 ± 9.4

1126

90

Tripterygium glycosides (72), other immunosuppressants (13.5), prednisolone (10)

Japan

Miyabe 2021 [62]

O-grade I c

30 (24–42)

260

25

Steroid + immunosuppressant (30)

Miyabe 2021 [62]

O-grade II c

30 (24–40)

525

35

Steroid + immunosuppressant (54)

Miyabe 2021 [62]

O-grade III c

34.5 (27–46.3)

86

49

Steroid + immunosuppressant (74)

Kaihan 2017 [60]

(n = 86)

36 (26–46)

86

84

Steroid (66), tonsillectomy (33), immunosuppressant (8)

Oshima 2015 [58]

20–39 years

27 (23–32)

162

30.5

Antiplatelet agents (55), steroid (37.8), tonsillectomy + steroid (18.7), immunosuppressant (2.5), tonsillectomy (1.7)

Oshima 2015 [58]

40–59 years

47 (43–52)

162

59

Antiplatelet agents (68.9), steroid (30.4), tonsillectomy + steroid (13.7), immunosuppressant (2.5), tonsillectomy (1.9)

Oshima 2015 [58]

≥ 60 years

64.5 (62–69)

31

67.7

Antiplatelet agents (58.1), steroid (51.6), immunosuppressant (3.2)

Sato 2015 [57]

42 (range, 18–73)

198

60.6

Steroid (59.1), immunosuppressant (59.1), tonsillectomy (1)

Moriyama 2014 [56]

33 ± 12

1,102

28.9

Antiplatelet agents (59.3), steroid (26.9), tonsillectomy + steroids (11.7%), tonsillectomy (1.5), steroid + immunosuppressant (1.5)

Matsuzaki 2013 [54]

NR

284

99.6

Antiplatelet agents (96.8), tonsillectomy + steroids (66.2), steroid pulse monotherapy (56), oral steroid (54.9%)

Goto 2009 [50]

32.1 (20.7–46.9)

2283

28.2

Steroid (34.5), immunosuppressant (10.6)

South Korea

Kee 2017 [71]

38.5 ± 13.1

574

83.4

Steroid (18.5), immunosuppressant (4)

Lee 2013 [68] d

35 (26–46)

1009

70.7

Steroid (12.4), immunosuppressant (3.4)

Lee 2010 [64]

38.1

177

27.7

ACEI/ARB + steroid (33.9), steroid (28.8), no treatment (8.5)

  1. Abbreviations: ACEI/ARB, angiotensin-converting enzyme inhibitor/angiotensin receptor blocker; NR, not reported
  2. a. Data is expressed as mean ± SD or median (then interquartile range)
  3. b. Patient > 14 years were included in the study
  4. c. O-grade is based on the Oxford classification system. Patients > 16 years were included in the study
  5. d. Patients > 15 years were included in the study
  6. e. Immunosuppressants were reported as a general type or specific drug (e.g., leflunomide, mycophenolate mofetil, tripterygium wilfordii, cyclophosphamide tacrolimus, etc.)
Back to article page

BMC Nephrology

ISSN: 1471-2369

Contact us